[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dependence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dependence":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100561251","phase-3-colchicine-for-the-reduction-of-dependency-and-vascular-events-after-an-acute-intracerebral-hemorrhage-100561251",false,"NCT06587737","Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage","A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors for, Atherosclerosis","CoVasc-ICH2","Inclusion Criteria:\n\nAdult patients presenting with spontaneous intraparenchymal hemorrhage within 72 hours of symptom onset and qualifying for at least one of the following categories:\n\ni. history of symptomatic coronary, peripheral and\u002For carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical\u002Fintracranial atherosclerotic disease causing any degree of stenosis\u002Focclusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL\u002Fmin), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease).\n\nExclusion Criteria:\n\n* secondary causes of ICH (such as trauma, macrovascular anomalies, neoplasms or bleeding diathesis)\n* ICH volume more than 60ml in the last imaging scan prior to consent\n* Glasgow Coma Scale (GCS) score less than 7 or being intubated at the time of consent\n* inflammatory bowel disease or chronic diarrhea\n* cirrhosis or severe hepatic dysfunction\n* renal insufficiency (eGFR\\\u003C15mL\u002Fmin)\n* concurrent or planned treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir\u002Fritonavir, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir\u002Fritonavir) or P-gp inhibitors (cyclosporine, ranolazine)\n* pregnancy or breast-feeding\n* known allergy or sensitivity to colchicine\n* a strong indication for colchicine where assignment to placebo is deemed unacceptable\n* estimated life expectancy less than 6 months at the time of enrollment, and\n* inability to adhere to study procedures","ALL","18 Years",{"count":20,"type":21},1125,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors.\n\nThe objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.",[27,28,29,30],"Colchicine","ICH - Intracerebral Hemorrhage","Stroke","Dependence","NOT_YET_RECRUITING","2026-02-23",{"date":34,"type":35},"2026-02-25","ACTUAL",{"date":37,"type":21},"2026-05-30",{"date":39,"type":21},"2028-10-30",{"name":41,"class":42},"Population Health Research Institute","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100544422","bridging-the-gap-creating-a-continuum-of-care-100544422","NCT06368674","Bridging the Gap: Creating a Continuum of Care","Bridging the Gap: Creating a Continuum of Care Through Active Follow-up by a Case Manager After Discharge - a Controlled Study","Inclusion Criteria:\n\n75 years or older, screened as frail, admitted to an acute geriatric ward working according to CGA at the Sahlgrenska or Mölndal hospital. Both hospitals are part of Sahlgrenska University hospital, with the same catchment area, including Gothenburg with surrounding municipalities. People in the region can seek care at both hospitals. The orthopaedic clinic is situated at Mölndal hospital, resulting in most patients with fractures being admitted to this hospital, irrespective of in which municipality they are living. Cognitive impairment is not an exclusion criterion. For people who cannot give informed consent due to cognitive impairment, next of kin will be asked to assist with the consent.\n\nExclusion Criteria:\n\nLess that 75 years old, Not residing in a permanent residence.","75 Years",{"count":52,"type":21},150,[54],"NA","Coordination and integration between care settings is essential for the quality of care of frail older patients. An active follow-up by a case manager (CM) after discharge form an acute geriatric hospital ward has the potential to bridge the gap between hospital, primary and municipality care for frail older people. This study evaluates the effects of an active follow-up by a CM in primary care after discharge from a geriatric ward, with the following research questions: Can an active follow-up by CM for frail older people discharged from an acute geriatric ward, compared to those not receiving active follow up, Maintain\u002Fincrease independence in activities of daily living, self-rated health and life satisfaction? Increase satisfaction with health care? Reduce health care consumption\u002Fbe cost-effective? How feasible is the intervention and the study design from the perspective of the caregivers and the older person? This is a clinical controlled study with a process evaluation. Inclusion criteria are 75 years or older, frail and admitted to a geriatric ward.\n\nThis study is relevant since today's highly specialized acute care is poorly adapted to the comprehensive needs of frail older people, and exposes them to avoidable risks such as loss of functional capacities causing unnecessary care needs and decreased wellbeing. Active follow-up by a CM after discharge may be an important way to integrate the care for frail older people, after receiving in-hospital geriatric care. This can improve the quality of care for this vulnerable group, and direct the right health care actions towards those in most need.\n\nThe intervention is a active follow-up after discharge by a CM (nurse) in primary care. CM will secure that discharge and care plans are executed and to address new needs. If there are unmet needs, the CM will ensure that adequate actions are performed to meet the needs. The intervention group consists of participants discharged to a primary health care centre with a CM, who actively follows-up after discharge. The control group consists of participants discharged to a primary health care centre without CM, and thereby no active follow-up after discharge. All participants will be followed-up by the research team during one year, concerning dependence in activities of daily living, self-rated health, health care consumption and satisfaction with care.",[57,30,58],"Frailty","Integrated Care",[60],"Person-centred care","RECRUITING","2025-04-09",{"date":64,"type":35},"2025-04-11",{"date":66,"type":35},"2024-06-06",{"date":68,"type":21},"2027-02-01",{"name":70,"class":42},"Göteborg University",1]